Medical Therapies Limited

Medical Therapies Limited (ASX: MTY), today announced that it has completed its 'first-in-human' clinical trial of Cuprindo(tm) to determine its safety, tolerability and systemic absorption characteristics. The Phase 1 trial was conducted using a topical suppository formulation in preparation for a planned efficacy study in proctitis patients.

Medical Therapies Limited (ASX: MTY) - Investor Presentation - Ms Maria Halasz , MD and CEO; Boardroomradio is pleased to announce that Medical Therapies Limited (ASX: MTY) has published an audio file.